Dendritic cell biology, dysfunction and immunotherapy in gastrointestinal cancers

Surgeon

Volumn 4, Issue 4, 2006, Pages 195-210

  Aloysius, Mark M ^a   Takhar, A ^a   Robins, A ^a   Eremin, Oleg ^a,b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

Cytotoxic T lymphocytes; Dendritic cells; Gastrointestinal cancers; Immunotherapy; T helper cells

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; BIOLOGICAL RESPONSE MODIFIER; CARCINOEMBRYONIC ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; FUNGUS ANTIGEN; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 3; KRESTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MESSENGER RNA; PICIBANIL; SECONDARY LYMPHOID TISSUE CHEMOKINE; T6 ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE ACTIVATION; BILE DUCT CARCINOMA; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELL MATURATION; CELL MIGRATION; CELL TRANSPLANTATION; CELL TYPE; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; HOST RESISTANCE; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHOID CELL; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREAS RESECTION; PATIENT MONITORING; PERITONEUM METASTASIS; PROGNOSIS; REVIEW; SKIN INDURATION; STOMACH CARCINOMA; SYNAPSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; THYROIDITIS; TUMOR IMMUNITY; VITILIGO;

EID: 33746684245     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(06)80061-2     Document Type: Review

References (157)

1. Office of National Statistics. 2005.
2. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein R et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188(7):1359-68.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392(6673):245-52.
4. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005; 5(2):112-24.
5. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196(12):1627-38.
6. Jang MH SN, Tanaka T, Sougawa N, Hirata T, Hiroi T, Tohya K et al. CCR 7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J Immunol 2006; 176(2):803-10.
7. Van Kooyk Y, Geijtenbeek TB, A novel adhesion pathway that regulates dendritic cell trafficking and T cell interactions. Immunol Rev 2002; 186:47-56.
8. Van, Gisbergen KP, Paessens LC, Geijtenbeek TB, van Kooyk Y. Molecular mechanisms that set the stage for DC-T cell engagement. Immunol Lett 2005; 97(2):199-208.
9. Lyubchenko TA, Wurth GA, Zweifach A. Role of calcium influx in cytotoxic T lymphocyte lytic granule exocytosis during target cell killing. Immunity 2001; 15(5):847-59.
10. Kummer JA, Kamp AM, Tadema TM, Vos W, Meijer CJ, Hack CE. Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol 1995; 100(1): 164-72.
11. Liu CC, Persechini PM, Young JD. Perforin and lymphocyte-mediated cytolysis. Immunol Rev 1995; 146:145-75.
12. Mariani E, Sgobbi S, Meneghetti A, Tadolini M, Tarozzi A, Sinoppi M et al. Perforins in human cytolytic cells: the effect of age. Mech Ageing Dev 1996; 92(2-3):195-209.
13. Pham CT, Ley TJ. The role of granzyme B cluster proteases in cell-mediated cytotoxicity. Semin Immunol 1997; 9(2): 127-33.
14. Liu ZX, Govindarajan S, Okamoto S, Dennert G. Fas-mediated apoptosis causes elimination of virus-specific cytotoxic T cells in the virus-infected liver. J Immunol 2001; 166(5):3035-41.
15. Waring P, Mullbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 1999; 77(4):312-17.
16. Atkinson EA, Bleackley RC. Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol 1995; 15(3-4):359-84.
17. Benz C, Hengel H. MHC class I-subversive gene functions of cytomegalovirus and their regulation by interferons-an intricate balance. Virus Genes 2000; 21(1-2):39-47.
18. Madiyalakan R, Yang R, Schultes BC, Baum RP, Noujaim AA, et al. OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA 125-specific allogenic cytotoxic T cells. Hybridoma 1997; 16(1):41-45.
19. Dimier IH, Bout DT. Interferon-gamma-activated primary enterocytes inhibit Toxoplasma gondii replication: a role for intracellular iron. Immunology, 1998; 94(4):488-95.
20. Nelson DE, Virok DP, Wood H, Roshik C, Johnson RM, Whitmore WM, et al. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc Natl Acad Sci U S A 2005; 102(30): 10658-63.
21. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988; 141(7):2407-12.
22. Heidenreich S, Weyers M, Gong JH, Sprenger H, Nain M, Gemsa D. Potentiation of lymphokine-induced macrophage activation by tumor necrosis factor-alpha. J Immunol 1988; 140(5):1511-18.
23. Guermonprez P, Valladeau J, Zitvogel L, Thery C. Amigorena S. Antigen presentation and T cells stimulation by dendritic cells. Ann Rev Immunol 2002: 20:621-67.
24. Chow A, Toomre D, Garrett W, Mellman I. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. [see comment]. Nature 2002; 418(6901):988-94.
25. Weiner HL. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol 2001; 2(8):671-72.
26. Rodrigues MM, Ribeirao M, Boscardin, SB. CD4 Th1 but not Th2 clones efficiently activate macrophages to eliminate Trypanosoma cruzi through a nitric oxide dependent mechanism. Immunol Lett 2000; 73(1):43-50
27. Tao X, Stout RD, T cell-mediated cognate signaling of nitric oxide production by macrophages. Requirements for macrophage activation by plasma membranes isolated from T cells. Eur J Immunol 1993; 23(11):2916-21.
28. Kindler V, Zubler RH. Memory, but not naive, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and costimulation with IL-4 and the differentiation factors IL-2, IL-10 and IL-3. J Immunol 1997; 159(5):2085-90.
29. Lee BO, Moyron-Quiroz J, Rangel Moreno J; Kusser KL, hartson L, Sprague F, et al. CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses. J Immunol 2003; 171(11):5707-17.
30. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2(3):151-61.
31. Shortman K, Wu L, Suss G, Kronin V, Winkel K, Saunders D, et al. Dendritic cells and T lymphocytes: developmental and functional interactions. Ciba Found Symp 1997; 204: 130-38; discussion 138-41.
32. Reid CD. The dendritic cell lineage in haemopoiesis. Br J Haematol 1997; 96(2)217-23.
33. Ardavin C. Thymic dendritic cells.[see comment]. Immunol Today 1997; 18(7)350-61.
34. Wu L, Scollay R, Egerton M, Pearse M, Spangrude GJ, Shortman K, et al. CD4 expressed on earliest T-lineage precursor cells in the adult murine thymus. Nature 1991; 349(6304):71-74.
35. Ardavin C, Wu L, Li CL, Shortman K. Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature 1993; 362(6422): 761-63.
36. Dalloul AH, Patry C. Salamero J, Canque B, Grassi F, Schmitt C. Functional and phenotypic analysis of thymic CD34+CD1a- progenitor-derived dendritic cells: predominance of CD1a+ differentiation pathway. J Immunol 1999: 162(10):5821-28.
37. Gally A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dentritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995; 3(4):459-73.
38. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YS. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185(6): 1101-11.
39. Shortman K, Caux C. Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells 1997; 15(6): 409-19.
40. Bykovskaia SN, Buffo M, Zhang H, Bunker M, Levitt ML, Agha M, et al. The generation of human dendritic and NK cells from hemopoietic progenitors induced by interleukin-15. J Leukoc Biol 1999, 66(4):659-66.
41. Bykovskaja SN, Buffo MJ, Bunker M, Zhang H, Majors A, Herbert M et al. Interleukin-2-induces development of denditric cells from cord blood CD34+cells. J Leukoc Biol 1998; 63(5):620-30.
42. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon.[see comment]. Nat Med 1999: 5(8):919-23.
43. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shan K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood.[see comment]. Science 1999; 284 (5421):1835-37.
44. Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, Timms E. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996; 84(4):551-62.
45. Suss G, Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 1996; 183(4): 1789-96.
46. Austyn JM. Dendritic cells. Curr Opin Hematol 1998;5(1): 3-15.
47. Metcalf D. Murine hematopoietic stem cells committed to macrophage/ dendritic cell formation: stimulation by F1K2-ligand with enhancement by regulations using the gp130 receptor chain. Proc Natl Acad Sci U S A 1997; 94(21): 11552-56.
48. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph mode dendritic cells in vivo. Immunity 1999; 11(6):753-61.
49. Peters JH, Gieseler R, Thiele B, Steinbach F. Dendritic cells: from ontogenetic orphans myelomonocytic descendants. Immunol Today 1996; 17(6):273-78.
50. Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, deSaint-Vis B, Jacquet C et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med 1996; 184(2):695-706.
51. Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997; 90(5):1920-26.
52. McRae BL, Semmani RT, Hayes MP, van Seventer GA. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol 1998; 160(9);4298-304.
53. Schaerli P, Willimann K, Ebert LM, Walz A, Moser B. Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity 2005: 23(3):331-42
54. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G. Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. [see comment]. Nat Immunol 2002; 3(7):673-80.
55. Santini SM, Di Pucchio T. Lapenta C. Parlato S, Logozzi M, Belardelli F. A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells 2003; 21(3):357-62.
56. de Saint-Vis B, Vincent J, Vandenabeele S, Vanbervliet B, Pin JJ, Ait-Yahia S, et al. A novel lysosome associated membrane glycoprotein, DC-LAMP induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998; 9(3);325-36.
57. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brajer J, et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003; 19(3);425-36.
58. Benvenuti F, Hugues S, Amigorena S. [Dendritic cell cytoskeleton mobilization to enhance antigen presentation]. Med Sci 2005; 21(1):13-15.
59. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3(12):984-93.
60. West MA, Wallin RP, Matthews SP, Svensson HG, Zaru R, Ljunggren HG, et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science 2004; 305(5687):1153-57.
61. Benvenuti F, Hugues S, Walmsley M, Ruf S, Fetler L, Popoff M, et al. Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming. Science 2004; 305(5687):1150-53.
62. Ohl L, Mohaupt M, Czeloth N, Hintzen G, Kiafard Z. Zwirnen J, et al CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 2004; 21(2):279-88.
63. Clemente CG, Mihm MC. Jr., Bufalino R, Zurrida S, Collini P. Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77(7): 1303-10.
64. Mihm MC, Jr., Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74(1):43-47.
65. Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secret granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1995; 1(1):95-103
66. Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, et al. Increased recurrence and metastasis in patients whose primary head and and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 1997; 74(1):69-74.
67. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunoly 2001; 166(1):678-89.
68. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6(5):1755-66.
69. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.[erratum appears in J Immunol 2004 Apr 1;172(7):4647]. J Immunol 2004; 172(2):989-99.
70. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
71. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396(6712):643-49.
72. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174(6):3798-807.
73. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004; 10(3):828-39.
74. Imai Y, Yamakawa M. Dendritic cells in esophageal cancer and lymph node tissues. In Vivo 1993; 7(3):239-48.
75. Ikeguchi M, Ikeda M, Tatebe S, Maeta M, Kaibara N. Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma. Onc Rep 1998; 5(5): 1185-89.
76. Huang HL, Wu BY, You WD, Shen MS, Wang WJ. [Influence of dendritic cell infiltration on prognosis and biologic characteristics of progressing gastric cancer]. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology] 2003; 25(5):468-71.
77. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159(1):103-8.
78. Ishigami S, Aikou T, Natsugoe S, Hokita S, Iwashige H, Tokushige M, et al. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology 1998; 55(1):65-9.
79. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimaghi K. Infiltration of S-100 protein positive dendritic cells and peritoneal recurrence in advanced gastric cancer. Int Surg 1992; 77(4):238-41.
80. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 1998; 78(12):1573-77.
81. Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells. IL-12 and endothelin-1. J Biol Regulat Homeost Agents 2001; 15(2):140-44.
82. Yamaguchi K, Saito H, Oro S, Tatebes S, Ikeguchi M. Tsujitani S. Expression of inducible nitric oxide synthase is significantly correlated with expression of vascular endothelial growth factor and dendritic cell infiltration in patients with advance gastric carcinoma. Oncology 2005; 68(4-6):471-78.
83. Zhou YJ, Xiong YX, Li CP, Shi D. Suppression of local immune response by GrB express in gastric cancer cells. Chinese Medical Journal 2004; 117(10):1573-75.
84. Takagi S, Miyagawa S, Ichikawa, E, Soeda, J, Miwa S, Miyagawa Y, et al. Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma. Hum Path 2004; 35(7):881-86.
85. Yanagimoto H, Takai S, Satoi S, Toyokawa H. Takahashi K, Terakawa N, et al, Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 2005; 114(1):52-60.
86. Dallal RM, Christakos P, Lee K, Egawa S, Son YI, Lotze MT. Paucity of dendritic cells in pancreatic cancer. Surgery 2002, 131(2): 135-38.
87. Feijoo E, Alfaro C, Mazzolini G, Serra P. Penuelas I, Arina A, et al. Dendritic cells delivered inside human carcinomas are sequestered by interleuki-8. Int J Cancer 2005; 116(2): 275-81.
88. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji N. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999; 31(2):323-31.
89. Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroentorol Hepatol 2000;15(4): 431-6.
90. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 2004; 10(21):7260-69.
91. Um SH, Mulhall C, Alisa A, Ives AR, Karani J, Williams R, et al. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 2004; 173(3):1772-78.
92. Chen S, Akbar SM, Tanimoto K, Ninomija T, Iuchi H, Michitaka K, et al. Absence: of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma:relevance to hepatocarcinogenesis Cancer Lett 2000; 148(1):49-57.
93. Cai XY Qiu SJ, WU ZQ, Ye SL, Fan J, Zhou J, Tang ZY. Relationship between dendritic cells and memory T lymphocytes in tumor site and prognosis of hepatocellular carcinoma. Chinese Medical Journal 2005; 85(10):671-5.
94. Yin X, Lu M, Liang L, Lai Y, Huang J, Li Z. [Infiltration of dendritic cells and lymphocytes in hepatocellular carcinoma tissue]. Chung-Hua Wai Ko Tsa Chin [Chinese Journal of Surgery] 2002;40(5):336-43.
95. Yin XY, Lu MD, Lai YR, Liang LJ, Huang JF. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterolgy 2003; 50(53):1281-84.
96. Schwaab T, Weiss JE, Schned AR, Barth RJ, Jr. Dendritic cell infiltration in colon cancer. J Immunother 2001; 24(2): 130-37.
97. Ambe K MM, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to clinical prognosis. Cancer 1989; 63:496-503.
98. Chaux P, Moutet M, Faivre J, Martin F, Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 1996; 74(5): 975-83.
99. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, et al. High levels of transforming growth factor beta-1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996; 110:375-82.
100. Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J. Lin F, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55:96-101.
101. Morse MA, Nair S, Fernandez-Casal M, Deng Y, St Peter M, Williams R, et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol 2000; 18(23): 3883-93.
102. Lynch DH. Induction of dendritic cells (DC) by flt3 ligand (FL) promotes the generation of tumour-specific immune responses in vivo. Crit Rev Immunol 1998; 18:99-107.
103. Favre-Felix N, Martin M, Maraskowsky E, Fromentin A, Moutet M Solary E, et al. Flt3 ligand lessens the growth of tumours obtained aftercolon cancer cell injection but does not restore tumour-suppressed dendritic cell function. Int J Cancer 2000; 86(6):827-34.
104. Pan PY, Li Y, Li Q, Gu P, Martinet O, Thung S, et al. In situ recruitment of antigen-presenting cells by intratumoural GM-CSF gene delivery. Cancer Immunol Immunother 2004; 53(1): 17-25.
105. Nagao N, Katoh M, Kumazawa I, Tomita H, Sugiyama Y, Kunieda K, et al. [A recurrent case of esophageal cancer in which metastatic skin tumor disappeared after local injection of activated lymphocytes with tumor-pulsed dendritic cells]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1999, 26(12):1937-39.
106. Kanaoka S, Yamasaki S, Okino T, Inoue E, Shimada Y, Kaneko M, et al. Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3-gene-derived peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an HLA-A2 esophageal cancer patient. J Surg Oncol 1999, 71(1): 16-21.
107. Sun HW, Tang QB, Cheng YJ, Zou SQ. Effects of dendritic cellls transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response. World J Gastroenterol 2004; 10(17):2595-97.
108. Liu BY, Chen XH, QL, Li JF, HR, Zhu ZG, et al. Antitumour effects of vaccine consisting of dendritic cells pulsed with tumour RNA from gastric cancer. World J Gastroenterol 2004; 10(5):630-33.
109. Ohshita A, Yamaguchi Y, Minami K, Miyahara E, Kawabuchi Y, Shimizu K, et al. Generation of TRiDAK (tumour RNA-introduced dendritic cell-activated killer) cells. Japanese Journal of Cancer & Chemotherapy 2003; 30(11):1809-12.
110. Ohta K Yamaguchi Y, Shimizu K, Miyahara E, Toge T. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells. Anticancer Res 2002; 22(5):2597-606.
111. Sun HW, Tang C, Tang QB, Zou SQ, Qui FZ. Study of immunological effect of dendritic cell transfected with survivin gene on the specific anti-alimentary tract tumour. Chinese Journal of Surgery 2005; 43(5):313-6.
112. Kim CH, Todoroki T, Matsumura M, Ohno T. Eligibility of antigenic-peptide-pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen. J Cancer Res Clin Oncol 2000; 126(7):383-90.
113. Shiku H, Wang L, Ikuta Y, Okugawa T, Schmitt M, Gu X, et al. Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol 2000; 46 Suppl: S77-82.
114. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induces specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002; 8(11): 3394-400.
115. Imura K, Yano Y, Naito K, Kouhara J, Ueda Y, Nakane K, et al. Immunogenic reactivity of CTLs induced by electrofusion cells of human dendritic cells and gastric cancer cells. Japanese Journal of Cancer & Chemotherapy 2004; 31(11):1797-99.
116. Anonymous. Cancer vaccine-Antigenics. Biodrugs 2002; 16(1):72-74.
117. Itoh T, Ueda Y, Okugawa K, Fujiwara H, Fuji N, Yamashita T, et al. Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother 2003; 52(4):207-14.
118. Okuzawa M, Shinohara H, Kobayashi T, Iwamoto M, Toyoda M, Tanigawa N. PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro. Int J Oncol 2002; 20(6): 1189-95.
119. Wu G, Han BL, Pei XT. [Immune response of dendritic cells acquiring antigens from apoptotic cholangiocarcinoma cells induced by mitomycin]. Chung Hua Kan Tsang Ping Tsa Chih 2003; 11(3):149-52.
120. Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, et al. The Feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 2002; 32(1):1-6.
121. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, et al. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. Int J Oncol 2003: 22(3):651-56.
122. McConnell EJ, Pathangey LB, Madsen CS, Gendler SJ, Mukherjee P. Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model. J Surg Res 2002; 107(2):196-202.
123. Kalady MF, Onaitis MW, Emani S, Abdul-Wahab Z, Pruitt SK, Tyler DS. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. J Gastrointest Surg 2004; 8(2):175-81; discussion 181-82.
124. Marten A, Schottker B, Ziske C, Weineck S, Buttgereit P, Huhn D, et al. Increase of the immunostimulatory effect of dendritic cells by pulsing with 19-9 protein. J Immunother 2000; 23(4):464-72.
125. Piper M, Goedegebuure PS, Eberlein TJ. Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells. Surgery 1997; 122(2):235-41; discussion 241-42.
126. Shimamura H, Sunamura M, Tsuchihara K, Egawa S, Takeda K, Matsumo S, Irradiated pancreatic cancer cells undergo both apoptosis and necrosis, and could be phagocytized by dendritic cells. Eur Surg Res 2005; 37(4):228-34.
127. Schueller G, Stiff A, Friedl J, Dubsky P, Bachleithner-Hofmann T, Benkoe T, et al. Hyperthermia improves cellular subsequent to co-culture with tumor lysate pulsed dendritic cells. Int J Oncol 2003; b(6):1397-402.
128. Wang XH, Qin Y, Hu MH, Xie Y. Dendritic cells pulsed with hsp 70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumour immune responses. World J Gastroenterol 2005; 11(36):5614-20.
129. Margalit M, Shibolet O, Klein A, Elinav E, ALper R, Thalenfeld B, et al. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes. Int Journal Cancer 2005; 115(3):443-49.
130. Gao J, Chen M, Ren H. clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperatibe recurrence and metastases of hepatocellular carcinoma. Chung Hua Kan, Tsang Ping Tsa Chih 2005; 13(6):432-35.
131. Lee WC, Wang H, Hung CF, Huang PF, Lia CR, Chen 0MF. Vaccination of advanced hepatocellular carcinoma patients with tumour-lysate pulsed dendritic cells: a clinical trial. J Immunother 2005; 28(5):496-504.
132. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002; 17(8):889-96.
133. Kumagil T, Akbar SM, Horiike N, Kurose K, Hirooka M, Hiraoka A, et al. Administration of dendritic cells in cancer nodules in hepatocellular carcinoma. Oncol Rep 2005; 14(4):969-73.
134. Wang XH, Qin Y, Hu MH, Xie Y. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother 2005; 54(10):971-80.
135. Yang JY, Ren J, Bai J, Liu DH, Fan L, Si Xm, et al. [Cytotoxicity induced by HBsAg gene modified-dendritic cells against hepatocellular carcinoma cell HepG2.2.15]. Ai Zheng 2004; 23(8):914-17.
136. Chan RC, Pang XW, Wang YD, Chen WF, Xie Y. Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells. Br J Cancer 2004; 90(8):1636-43.
137. Guan X, Peng JR, Yuan L, Wang H, Wei YH, Leng XS. A novel, rapid strategy to form dendritomas from human dendritic cells and hepatocellular carcinoma cell line HCCLM3 cells using mature dendritic cells derived from human peripheral blood CD14+ monocytes within 48 hours of in vitro culture. World J Gastroenterol 2004; 10(24): 3564-68.
138. Guan X, Peng JR, Leng XS. Establishment of dentritomas by fusion of human dentritic cells with human hepatocellular carcinoma cell line HLE cells. Chung Hua Kan Tsang Ping Tsa Chih 2005; 27(8):465-67.
139. Nakamori M, Iwahashi M, Tani M, Yamaue H, Ueda K, Matsuda K, et al. New therapeutic strategy against colon cancer based on a tumour-specific approach Japanese Journal of Cancer & Chemotherapy 2000; 27(14):2209-15.
140. Eppler E, Horig H, Kaufman HL, Groscurth P, Filgueria L. Carcinoembryonic antigen (CEA) presentation and and specific T cell-priming by human dentritic cells transfected with CEA-mRNA. Eur J Cancer 200; 38(1):184-93.
141. Brossart P, Stuhler G, Flad T, Stevanovic R, Rammensec HG, Kanz L, et al. Her-2/neu-derived peptides are tumor-assciated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes Cancer Res 1998; 58(4): 732-36.
142. Nencioni A, Muller MR, Grunebach F, Garuti A, Mingari MC, Patrone F, et al. Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther 2003; 10(3):209-14.
143. Nair SK, Morse M, Boczkowski D, Cumming I, Vasovic L, Gilboa E, et al. Induction of tumour-specific cytotoxic T lymphocytes in cancer patients by autologaus tumour RNA-transfected dendritic cells. Ann Surg 2002; 235(4):540-49.
144. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dentritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Repatogastroenterology 2001 48(38): 347-51.
145. Inoue N, Yamasaki S, Kondo K, Kan T, Furumoto K, Imamura M. Dendritic cells coinjected with tumour cells treated with an anti cancer drug to induce tumour rejection. Surg Today 2003; 33(4):269-76.
146. Xu F, Ye YG, Wang S. In vitro antitumour immune response induced by fusion of dendritic cells and colon cancer cells. W J Gastroenterology 2004; 10(8):1162-166.
147. Xu F, Ye YG, Cui ZR, Wan S. Allogeneic dendritomas induce anti-tumourimmunity against mertastatic colon cancer. Scand Immunol 2005; 61:364-69.
148. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. Tumour-derived TGF-beta reduces the efficacy of dendritic: cell/tumour fusion vaccine. J Immunol 2003; 170(7):3806-11.
149. Altman JD, Moss PA, Goulder PJR, Barouch, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen specific T lymphocytes. Science 1996; 274:94-96.
150. Herr W, Linn B, Leister N, Wandel E, Meyer zum Buschenfelde KH, Wolfel T. The use of computer-assisted video image analysis for quantification of CD8+T lymphocytes producing tumour necrosis factor alpha spots in response to peptide antigens. J Immunol Methods 1997; 203:141-52.
151. Betts MR, Brenchley JM, Price DA, DeRosa SC, Douek DC, Roedere M, Koup RA. Sensitive and viable identication of antigen-specific CD8+T cells by a flowcytometric assay for degranulation. J Immunol Methods 2003; 281(1-2):65-78.
152. Ficher K, Anderson R, Mackensen A. An improved flocytometric assay for the determination of cytotoxic T lymphocyte activity. J Immunol Methods 2002; 259(1-2): 159-69.
153. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen specific CD4+T cells with diverse cytokine profiles. Nat Med 2005; 11(10):1113-17.
154. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical response in patients with metastatic melanoma to CD34(+) progenitor-derived dentritic cell vaccine. Cancer Res 2001; 61(17): 6451-58.
155. Escobar A, Lopez M, Serrano, Ramirez M, Perez C, Aguirre A, et al. Dentritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005; 142(3):555-68.
156. Chianeste-Bullock KA, Woodson EM, Tao H, Boerner SA Smolkin M, Grosh WW, et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunoth 2005; 28(4):412-19.
157. Danet-Desnoyers GA, Luongo J, Bonnel DA, Domchek SM, Vonderheide RH. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Expl Hematol 2005; 33(11):1275-80.